Experimental change on dopaminergic neurons in striatum of Parkinson disease rats

Histology and Histopathology

Volumn 22, Issue 10-12, 2007, Pages 1085-1090

  Chen, Xiaoyu ^a   Li, Jun ^a   Qi, W Q ^a   Shen, S H ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

6 hydroxydopamine; Apomorphine; c jun; Striatum; Tyrosine hydroxylase

Indexed keywords

APOMORPHINE; OXIDOPAMINE; PROTEIN C JUN; TYROSINE 3 MONOOXYGENASE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL DEGENERATION; NISSL STAINING; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; UPREGULATION; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NERVE CELL; PATHOLOGY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

RATTUS;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; MALE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPIC MOVEMENT DISORDER; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 34547562987     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Behrens A., Sibilia M. and Wagner E.F. (1999). Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat. Genet. 21, 326-329.
2. Ben-Shlomo Y. and Sieradzan K. (1995). Idiopathic Parkinson's disease: epidemiology, diagnosis and management. Br. J. Gen. Pract. 45, 261-268.
3. Borlongan C.V. and Sanberg P.R. (1995). Elevated body swing test: a new behavioural parameter for rats with 6-hydroxydopamine-induced hemi-parkinsonism. J. Neurosci. 15, 5372 - 5378.
4. Brecht S., Kirchhof R., Chromik A., Willesen M., Nicolaus T., Raivich G., Wessig J., Waetzig V., Goetz M., Claussen M., Pearse D., Kuan C.Y., Vaudano E., Behrens A. and Wagner G. (2005). Specific patho-physiological functions of JNK isoforms in the brain. Eur. J. Neurosci. 21, 363-377.
5. Dauer W. and Przedborski S. (2003). Parkinson's disease: mechanisms and models. Neuron 39. 889-909.
6. Henderson J.M., Watson S., Halliday G.M., Heinemann. T. and Gerlach M. (2003). Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav. Brain Res. 139, 105-113.
7. Henry B., Crossman A.R. and Brotchie J.M. (1998). Characterization of enhanced behavioral responses to L-dopa following repeated administration in the 6-hydroxydopamine lesioned rat model of Parkinson's disease. Exp. Neurol. 151, 334-342.
8. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B.J. and Gerhardt G.A. (1993). Correlation of apomorphine-and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626, 167-174.
9. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C. and Przedborski S. (2004). JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 101, 665-670.
10. Iancu R., Mohapel P., Brundin P. and Paul G. (2005). Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res 162, 1-10.
11. Ischiropoulos H. and Beckman J.S. (2003). Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J. Clin. Invest. 111, 163-169.
12. Lindvall O. and Björklund A. (2004). Cell therapy in Parkinson's disease. NeuroRx. 1, 382-393.
13. Moore A.E., Cicchetti F., Hennen J. and Isacson O. (2001). Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat. Exp. Neurol. 172, 363-376.
14. Perrier A.L., Tabar V., Barberi T., Rubio M.E., Bruses J., Topf N., Harrison N.L. and Studer L. (2004). Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 101, 12543-12548.
15. Pignatelli A., Kobayashi K., Okano H. and Belluzzi O. (2005). Functional properties of dopaminergic neurones in the mouse olfactory bulb. J. Physiol. 564, 501-514.
16. Rothblat D.S., Schroeder J.A. and Schneider J.S. (2001). Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery tram experimental Parkinsonism. J. Neurosci. Res. 65, 254-266.
17. Saporito, M.S., Brown E.M., Miller M.S. and Carswell S. (1999). CEP-1347/ KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine mediated loss of nigrostriatal dopaminergic neurons In vivo. Pharmacol. Exp. Therapet. 288, 421-427.
18. Schwarting R.K. and Huston J.P. (1996). The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331.
19. Zhen X., Uryu K., Wang H.Y. and Friedman E. (1998). D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. Mol. Pharmacol. 54, 453-458.